

Initial REMS Approval: 10/19/2009  
Most Recent Modification: 10/15/2014

NDA 21-928  
Chantix<sup>®</sup> (Varenicline) Tablets  
Nicotinic Receptor Partial Agonist  
Aid to Smoking Cessation

Pfizer Inc  
235 East 42<sup>nd</sup> Street  
New York, NY 10017-5755  
212-733-2323

**RISK EVALUATION AND MITIGATION STRATEGY (REMS)**

**I. GOAL**

The goal of this REMS is to inform patients about the potential serious risk of neuropsychiatric adverse events associated with the use of CHANTIX.

**II. REMS ELEMENTS**

**A. Medication Guide**

A Medication Guide will be dispensed with each Chantix (varenicline) prescription in accordance with 21 CFR 208.24.

**B. Timetable for Submission of Assessments**

Pfizer will submit REMS Assessments to FDA 18 months, 3 years, and 7 years following the initial REMS approval of October 19, 2009. To facilitate inclusion of as much information as possible, while allowing reasonable time to prepare the submission, the reporting interval covered by each assessment should conclude no earlier than 60 days before the submission date for that assessment.

Pfizer Inc will submit each assessment so that it will be received by the FDA on or before the due date.

-----  
**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**  
-----

/s/  
-----

RIGOBERTO A ROCA  
10/15/2014